We have located links that may give you full text access.
Urantide Improves Cardiac Function, Modulates Systemic Cytokine Response and Increases Survival in a Murine Model of Endotoxic Shock.
Shock 2019 September 18
INTRODUCTION: Urotensin II (UII) is a potent vasoactive peptide activating the G protein-coupled receptor UT, and is involved in systemic inflammation and cardiovascular functions. The aim of our work was to study the impact of the UT antagonist urantide on survival, systemic inflammation and cardiac function during endotoxic shock.
METHODS: C57Bl/6 mice were intraperitoneally injected with lipopolysaccharide (LPS) and then randomized to be injected either by urantide or NaCl 0.9% 3, 6 and 9 hours (H3, H6, H9) after LPS. The effect of urantide on the survival rate, the levels of cytokines in plasma at H6, H9, H12, the expression level of nuclear factor-kappa B (NF-κB-p65) in liver and kidney (at H12), and the cardiac function by trans-thoracic echocardiography from H0 to H9 was evaluated.
RESULTS: Urantide treatment improved survival (88.9% vs 30% on day 6, p < 0.05). This was associated with changes in cytokine expression: a decrease in IL-6 (2485 [2280-2751] pg/ml vs 3330 [3119-3680] pg/ml, p < 0.01) at H6, in IL-3 (1.0 [0.40-2.0] pg/ml vs 5.8 [3.0-7.7] pg/ml, p < 0.01), and IL-1β (651 [491-1135] pg/ml vs 1601 [906-3010] pg/ml, p < 0.05) at H12 after LPS administration. Urantide decreased the proportion of cytosolic NF-κB-p65 in liver (1.3 [0.9-1.9] vs 3.2 [2.3-4], p < 0.01) and kidney (0.3 [0.3-0.4] vs 0.6 [0.5-1.1], p < 0.01). Urantide improved cardiac function (left ventricular fractional shortening: 24.8 [21.5-38.9] vs 12.0 [8.7-17.6] %, p < 0.01 and cardiac output: 30.3 [25.9-39.8] vs 15.1 [13.0-16.9] ml/min, p < 0.0001).
CONCLUSION: These results show a beneficial curative role of UT antagonism on cytokine response (especially IL-3), cardiac dysfunction and survival during endotoxic shock in mice, highlighting a potential new therapeutic target for septic patients.
METHODS: C57Bl/6 mice were intraperitoneally injected with lipopolysaccharide (LPS) and then randomized to be injected either by urantide or NaCl 0.9% 3, 6 and 9 hours (H3, H6, H9) after LPS. The effect of urantide on the survival rate, the levels of cytokines in plasma at H6, H9, H12, the expression level of nuclear factor-kappa B (NF-κB-p65) in liver and kidney (at H12), and the cardiac function by trans-thoracic echocardiography from H0 to H9 was evaluated.
RESULTS: Urantide treatment improved survival (88.9% vs 30% on day 6, p < 0.05). This was associated with changes in cytokine expression: a decrease in IL-6 (2485 [2280-2751] pg/ml vs 3330 [3119-3680] pg/ml, p < 0.01) at H6, in IL-3 (1.0 [0.40-2.0] pg/ml vs 5.8 [3.0-7.7] pg/ml, p < 0.01), and IL-1β (651 [491-1135] pg/ml vs 1601 [906-3010] pg/ml, p < 0.05) at H12 after LPS administration. Urantide decreased the proportion of cytosolic NF-κB-p65 in liver (1.3 [0.9-1.9] vs 3.2 [2.3-4], p < 0.01) and kidney (0.3 [0.3-0.4] vs 0.6 [0.5-1.1], p < 0.01). Urantide improved cardiac function (left ventricular fractional shortening: 24.8 [21.5-38.9] vs 12.0 [8.7-17.6] %, p < 0.01 and cardiac output: 30.3 [25.9-39.8] vs 15.1 [13.0-16.9] ml/min, p < 0.0001).
CONCLUSION: These results show a beneficial curative role of UT antagonism on cytokine response (especially IL-3), cardiac dysfunction and survival during endotoxic shock in mice, highlighting a potential new therapeutic target for septic patients.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app